Adjuvant Therapy of Colon Cancer: Current Status and Future Developments

 

 Buy Article Permissions and Reprints

ABSTRACT

Options for the adjuvant therapy of resected stage III colon cancer have expanded beyond the previously well-accepted standard of 5-fluorouracil (5-FU) combined with leucovorin. The Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) study confirmed that capecitabine (Xeloda) is at least as effective and is less toxic than a bolus 5-FU and leucovorin regimen for patients with stage III colon cancer. This study, in addition to National Surgical Adjuvant Breast and Bowel Project (NSABP) C-06, which demonstrated the equivalence of tegafur-uracil (UFT)/leucovorin with 5-FU/leucovorin, provides support for use of oral fluoropyrimidines for adjuvant therapy. Support for use of multiagent chemotherapy has been provided by the European MOSAIC study, which demonstrated a significant improvement in 3-year disease-free survival for the addition of oxaliplatin (Eloxatin) to infusional 5-FU and leucovorin (FOLFOX). Although adding irinotecan (Camptosar) to a bolus 5-FU and leucovorin regimen did not improve outcome in the adjuvant setting, the PETACC studies are evaluating the combination of infusional 5-FU, leucovorin, and irinotecan. In contrast to agreement on the appropriateness of therapy for stage III colon cancer, adjuvant therapy for patients with stage II disease remains controversial. Future advances in adjuvant therapy may include targeted therapies. Based on data demonstrating efficacy for the monoclonal antibodies bevacizumab (Avastin) and cetuximab (Erbitux) in the metastatic setting, clinical trials adding these agents to standard chemotherapy have been initiated in the adjuvant setting. Specifically, one U.S. cooperative group trial will evaluate the addition of bevacizumab to chemotherapy, a second will assess the addition of cetuximab, and a third trial will evaluate FOLFOX, infusional 5-FU/leucovorin (FOLFIRI), and FOLFOX followed by FOLFIRI. Finally, a study for patients with stage II disease and adverse prognostic factors will open. An important consideration in the new clinical trials is an assessment of molecular markers that either predict response or resistance to therapy or provide other prognostic information.

REFERENCES

• 1 Cheng X, Chen V W, Steele B et al.. Subsite-specific incidence rate and stage of disease in colorectal cancer by race, gender, and age group in the United States, 1992-1997.  Cancer. 2001;  92 2547-2554
  CrossrefPubMedGoogle Scholar
• 2 O'Connell J B, Maggard M A, Ko C Y. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging.  J Natl Cancer Inst. 2004;  96 1420-1425
  PubMedGoogle Scholar
• 3 Grage T B, Moss S E. Adjuvant chemotherapy in cancer of the colon and rectum: demonstration of effectiveness of prolonged 5-FU chemotherapy in a prospectively controlled, randomized trial.  Surg Clin North Am. 1981;  61 1321-1329
  PubMedGoogle Scholar
• 4 Higgins G A, Humphrey E, Juler G, LeVeen H H, McCaughan J, Keehn R J. Adjuvant chemotherapy in the surgical treatment of large bowel cancer.  Cancer. 1976;  38 1461-1467
  PubMedGoogle Scholar
• 5 Wolmark N, Fisher B, Rockette H et al.. Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01.  J Natl Cancer Inst. 1988;  80 30-36
  PubMedGoogle Scholar
• 6 Laurie J A, Moertel C G, Fleming T R et al.. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic.  J Clin Oncol. 1989;  7 1447-1456
  PubMedGoogle Scholar
• 7 Moertel C G, Fleming T R, Macdonald J S et al.. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma.  N Engl J Med. 1990;  322 352-358
  CrossrefPubMedGoogle Scholar
• 8 Moertel C G, Fleming T R, Macdonald J S et al.. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report.  Ann Intern Med. 1995;  122 321-326
  CrossrefPubMedGoogle Scholar
• 9 Wolmark N, Rockette H, Fisher B et al.. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03.  J Clin Oncol. 1993;  11 1879-1887
  CrossrefPubMedGoogle Scholar
• 10 Taal B G, Van Tinteren H, Zoetmulder F A. Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III.  Br J Cancer. 2001;  85 1437-1443
  CrossrefPubMedGoogle Scholar
• 11 O'Connell M J, Laurie J A, Kahn M et al.. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer.  J Clin Oncol. 1998;  16 295-300
  PubMedGoogle Scholar
• 12 Haller D G, Catalano P J, Macdonald J S, Mayer R J. Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: five-year final report of int-0089.  Proc Am Soc Clin Oncol. 1998;  , abstract #982
  PubMedGoogle Scholar
• 13 Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. QUASAR Collaborative Group.  Lancet. 2000;  355 1588-1596
  CrossrefPubMedGoogle Scholar
• 14 Sargent D J, Goldberg R M, Jacobson S D et al.. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients.  N Engl J Med. 2001;  345 1091-1097
  CrossrefPubMedGoogle Scholar
• 15 Smith R E, Colangelo L, Wieand H S, Begovic M, Wolmark N. Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01.  J Natl Cancer Inst. 2004;  96 1128-1132
  PubMedGoogle Scholar
• 16 Twelves C, Wong A, Nowacki M P et al.. Capecitabine as adjuvant treatment for stage III colon cancer.  N Engl J Med. 2005;  352 2696-2704
  CrossrefPubMedGoogle Scholar
• 17 Wolmark N, Wieand S, Lembersky B et al.. A phase III trial comparing oral UFT to FULV in stage II and III carcinoma of the colon: results of NSABP protocol C-06.  Proc Am Soc Clin Oncol. 2004;  22 2 , abstract 3508
  PubMedGoogle Scholar
• 18 Sakamoto J, Ohashi Y, Hamada C et al.. Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials.  J Clin Oncol. 2004;  22 484-492
  PubMedGoogle Scholar
• 19 Andre T, Boni C, Mounedji-Boudiaf L et al.. Multicenter international study of oxaliplatin/5-fluorouracil/leucovorin in the adjuvant treatment of colon cancer (MOSAIC) investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.  N Engl J Med. 2004;  350 2343-2351
  CrossrefPubMedGoogle Scholar
• 20 De Gramont A, Boni C, Navarro M. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: efficacy results with a median follow-up of 4 years.  ASCO. 2005;  , Gastrointestinal Cancers Symposium. Abstract #167
  PubMedGoogle Scholar
• 21 Sargent D J, Wieand S, Benedetti J et al.. Disease-free survival (DFS) vs. overall survival (OS) as a primary endpoint for adjuvant colon cancer studies: individual patient data from 12,915 patients on 15 randomized trials.  Proc Am Soc Clin Oncol. 2004;  , abstract #3502
  PubMedGoogle Scholar
• 21a Wolmark N, Wieand H S, Kuebler J P, Colangelo L, Smith R E. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: results of NSABP Protocol C-07.  Proc Am Soc Clin Oncol. 2005;  23 LBA3500
  PubMedGoogle Scholar
• 22 Figer A, Perez N, Carola E et al.. 5-Fluorouracil, folinic acid and oxaliplatin (FOLFOX) in very old patients with metastatic colorectal cancer.  J Clin Oncol. 2004;  22(14S) (July 15 suppl) , abstract 3571
  PubMedGoogle Scholar
• 23 Tournigand C, Andre T, Achille E et al.. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.  J Clin Oncol. 2004;  22 229-237 , Epub 2003 Dec 02
  CrossrefPubMedGoogle Scholar
• 24 Saltz L B, Niedzwiecki D, Hollis D et al.. Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803).  J Clin Oncol. 2004;  22(14S) , abstract #3500
  PubMedGoogle Scholar
• 24a Van Cutsem E, Labianca R, Hossfeld D. Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts).  , (PETACC 3.) Proc Am Soc Clin Oncol. 2005;  23 LBA8
  PubMedGoogle Scholar
• 24b Ychou M, Raoul J, Douillard J et al.. A phase III randomized trial of LV5FU2 + CPT-11 vs. LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802).  Proc Am Soc Clin Oncol. 2005;  23 3502
  PubMedGoogle Scholar
• 25 Mamounas E, Wieand S, Wolmark N. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04).  J Clin Oncol. 1999;  17 1349-1355
  PubMedGoogle Scholar
• 26 Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) investigators.  J Clin Oncol. 1999;  17 1356-1363
  PubMedGoogle Scholar
• 27 Gray R G, Barnwell J, Hills R et al.. QUASAR: a randomized study of adjuvant chemotherapy (CT) vs observation including 3238 colorectal cancer patients.  J Clin Oncol. 2004;  (14S) , abstract 3501
  PubMedGoogle Scholar
• 28 Hickish T, Boni C, Navarro M et al.. FOLFOX4 as adjuvant treatment for stage II colon cancer (CC): subpopulation data from the MOSAIC trial.  J Clin Oncol. 2004;  22(14S) , abstract #3619
  PubMedGoogle Scholar
• 29 Figueredo A, Charette M L, Maroun J, Brouwers M C, Zuraw L. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group.  J Clin Oncol. 2004;  22 3395-3407
  CrossrefPubMedGoogle Scholar
• 30 Benson III A B, Schrag D, Somerfield M R et al.. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer.  J Clin Oncol. 2004;  22 3408-3419
  CrossrefPubMedGoogle Scholar
• 31 Chirieac L, Suehiro Y, Niemisto A et al.. Size and number of examined lymph nodes impacts outcome in patients with stage II colorectal cancer.  J Clin Oncol. 2004;  22(14S) , abstract #3507
  PubMedGoogle Scholar
• 32 Petersen V C, Baxter K J, Love S B, Shepherd N A. Identification of objective pathological prognostic determinants and model of prognosis in Dukes' B colon cancer.  Gut. 2002;  51 65-69
  CrossrefPubMedGoogle Scholar
• 33 Wolmark N, Bryant J, Smith R et al.. Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05.  J Natl Cancer Inst. 1998;  90 1810-1816
  PubMedGoogle Scholar
• 34 Riethmuller G, Schneider-Gadicke E, Schlimok G et al.. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group.  Lancet. 1994;  343 1177-1183
  CrossrefPubMedGoogle Scholar
• 35 Riethmuller G, Holz E, Schlimok G et al.. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial.  J Clin Oncol. 1998;  16 1788-1794
  PubMedGoogle Scholar
• 36 Fields A L, Keller A M, Schwartzberg L et al.. Edrecolomab (17-1A antibody) (EDR) in combination with 5-fluorouracil (FU) based chemotherapy in the adjuvant treatment of stage III colon cancer: results of a randomised North American phase III study.  Proc Am Soc Clin Oncol. 2002;  , abstract #508
  PubMedGoogle Scholar
• 37 Punt C J, Nagy A, Douillard J Y et al.. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study.  Lancet. 2002;  360 671-677
  CrossrefPubMedGoogle Scholar
• 38 Colacchio T A, Niedzwiecki D, Compton C et al.. Phase III trial of adjuvant immunotherapy with MOAb 17-1A following resection for stage II adenocarcinoma of the colon (CALGB 9581).  J Clin Oncol. 2004;  22(14S) , abstract #3522
  PubMedGoogle Scholar
• 39 Hoover Jr H C, Brandhorst J S, Peters L C et al.. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial.  J Clin Oncol. 1993;  11 390-399
  PubMedGoogle Scholar
• 40 Vermorken J B, Claessen A M, van Tinteren H et al.. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial.  Lancet. 1999;  353 345-350
  CrossrefPubMedGoogle Scholar
• 41 Harris J E, Ryan L, Hoover Jr H C et al.. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283.  J Clin Oncol. 2000;  18 148-157
  PubMedGoogle Scholar
• 42 Ishioka G Y, Disis M L, Morse M A et al.. A phase I trial of a multi-epitope cancer vaccine (EP-2101) in non-small cell lung (NSCLC) and colon cancer patients.  J Clin Oncol. 2004;  22(14S) , abstract #2525
  PubMedGoogle Scholar
• 43 Gill S, Loprinzi C L, Sargent D J et al.. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?.  J Clin Oncol. 2004;  22 1797-1806
  CrossrefPubMedGoogle Scholar
• 44 Ribic C M, Sargent D J, Moore M J et al.. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.  N Engl J Med. 2003;  349 247-257
  CrossrefPubMedGoogle Scholar
• 45 Watanabe T, Wu T T, Catalano P J et al.. Molecular predictors of survival after adjuvant chemotherapy for colon cancer.  N Engl J Med. 2001;  344 1196-1206
  CrossrefPubMedGoogle Scholar
• 46 Edler D, Glimelius B, Hallstrom M et al.. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy.  J Clin Oncol. 2002;  20 1721-1728
  CrossrefPubMedGoogle Scholar
• 47 Cascinu S, Graziano F, Valentini M et al.. Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: relationships with tumor recurrence and resistance to adjuvant chemotherapy.  Ann Oncol. 2001;  12 239-244
  CrossrefPubMedGoogle Scholar
• 48 Allegra C J, Paik S, Colangelo L H et al.. Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study.  J Clin Oncol. 2003;  21 241-250
  CrossrefPubMedGoogle Scholar

Michael A MorseM.D. 

Division of Medical Oncology, Box 3233, Rm. 3803 Red Zone

Duke South Clinics, Duke University Medical Center

Durham, NC 27710

Email: michael.morse@duke.edu